Immutep Limited American Depositary Shares
IMMP
IMMP: Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.
moreShow IMMP Financials
Recent trades of IMMP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMMP's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response Feb. 21, 2023
-
Patent Title: Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response Mar. 19, 2019
-
Patent Title: Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response Feb. 28, 2017
Federal grants, loans, and purchases
Followers on IMMP's company Twitter account
Number of mentions of IMMP in WallStreetBets Daily Discussion
Recent insights relating to IMMP
Recent picks made for IMMP stock on CNBC
ETFs with the largest estimated holdings in IMMP
Flights by private jets registered to IMMP